Home › Research › Treatments
Efficacy, safety, and ARIA risk of anti-β-amyloid antibodies in early Alzheimer's disease: a systematic review, meta-analysis, and meta-regression
da Silva AMP, de Deus O, Januário Campos Cardoso L, Virgilio Ribeiro F, Froelich Meldola P, Rodrigues Menezes I, Lee Han M, Quiroga DG et al.. Expert opinion on biological therapy, 2026-01-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Background Alzheimer's disease (AD) is the most prevalent cause of dementia and has been closely linked to βSupplemental data for this article can be accessed online at ht tps://doi.org/-amyloid accumulation. However, the efficacy and safety of anti-β-amyloid monoclonal antibodies remain debated. Methods We systematically searched PubMed, Embase, and Cochrane databases for RCTs comparing anti-β-amyloid monoclonal antibodies with placebo in early-stage AD. Eligible trials enrolled participants with biomarker-supported AD and reported global, cognitive, or safety outcomes, including the CDR-SB, ADAS-Cog 13/14, ARIA, and brain volumetric measures. Results Six RCTs including 7837 participants were analyzed. Mean age ranged from 69.8 to 75.4 years, and 57.4% were APOE ε4 carriers. Anti-β-amyloid therapy was associated with small differences in global and cognitive outcomes, best described as a modest slowing of decline on the CDR-SB and ADAS-Cog scales. Treatment was associated with increased risks of ARIA-E (RR, 9.40; 95% CI, 6.98-12.66) and ARIA-H (RR, 2.40; 95% CI, 2.08-2.78), as well as greater ventricular enlargement and hippocampal atrophy. Conclusion In early AD, anti-β-amyloid monoclonal antibodies are associated with modest slowing of decline accompanied by increased ARIA risk and unfavorable structural brain changes, limiting clinical applicability. Protocol registration www.crd.york.ac.uk/prospero identifier is CRD420251071393.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
da Silva, A. M. P., de Deus, O., Januário Campos Cardoso, L., Virgilio Ribeiro, F., Froelich Meldola, P., Rodrigues Menezes, I., et al. (2026). Efficacy, safety, and ARIA risk of anti-β-amyloid antibodies in early Alzheimer's disease: a systematic review, meta-analysis, and meta-regression. Expert opinion on biological therapy. https://doi.org/10.1080/14712598.2026.2631536
Vancouver
da Silva AMP, de Deus O, Januário Campos Cardoso L, Virgilio Ribeiro F, Froelich Meldola P, Rodrigues Menezes I, et al. Efficacy, safety, and ARIA risk of anti-β-amyloid antibodies in early Alzheimer's disease: a systematic review, meta-analysis, and meta-regression. Expert opinion on biological therapy. 2026. doi:10.1080/14712598.2026.2631536. PMID: 41671691.
BibTeX
@article{dasilva2026-41671691,
author = {da Silva, A. M. P. and de Deus, O. and Januário Campos Cardoso, L. and Virgilio Ribeiro, F. and Froelich Meldola, P. and Rodrigues Menezes, I. and Lee Han, M. and Quiroga, D. G. and others},
title = {{Efficacy, safety, and ARIA risk of anti-β-amyloid antibodies in early Alzheimer's disease: a systematic review, meta-analysis, and meta-regression}},
journal = {Expert opinion on biological therapy},
year = {2026},
doi = {10.1080/14712598.2026.2631536},
pmid = {41671691},
url = {https://doi.org/10.1080/14712598.2026.2631536}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Results Six RCTs including 7837 participants were analyzed.
- Anti-β-amyloid therapy was associated with small differences in global and cognitive outcomes, best described as a modest slowing of decline on the CDR-SB and ADAS-Cog scales.
- Treatment was associated with increased risks of ARIA-E (RR, 9.40; 95% CI, 6.98-12.66) and ARIA-H (RR, 2.40; 95% CI, 2.08-2.78), as well as greater ventricular enlargement and hippocampal atrophy.
- Conclusion In early AD, anti-β-amyloid monoclonal antibodies are associated with modest slowing of decline accompanied by increased ARIA risk and unfavorable structural brain changes, limiting clinical applicability.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Participants7,837
- Effect size57.4%
- Evidence strengthLow
How this study scored 78/100
Published in a peer-reviewed journal, and it is a meta-analysis pooling many studies. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multicenter collaboration, so those were left out: it earned 45 of the 58 points we could judge it on, which is 78 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Expert opinion on biological therapy) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 12 / 12 | A meta-analysis pooling many studies (from PubMed type “Meta-Analysis”) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 3 / 4 | 7,837 participants |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | A review of other studies — randomization is not credited here |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 41671691) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 45 / 58 | Scored on 11 of 20 parts. We have no data for the rest, so they are left out: 45 of the 58 points we could judge it on is 78 out of 100. |
| Total | 78 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Treatments from nearby years
Also tagged “efficacy-safety”
2 studies in the library carry the topic tag “efficacy-safety”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 2 tagged studies.